NEWS
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
Elutia Inc. (Nasdaq: ELUT) has announced the first patient implant of EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac pacemakers and neurostimulators.
The procedure was performed by Dr. John Catanzaro at East Carolina University Health Medical Center. EluPro is designed to prevent post-operative complications in patients with implantable devices.
Cleared by the FDA in June 2024, EluPro targets the $600 million U.S. implantable electronic device protection market. Elutia aims to establish a presence in the $8 billion cardiac rhythm management market and adjacent $8 billion neurostimulation sectors.
Cleared by the FDA in June 2024, EluPro targets the $600 million U.S. implantable electronic device protection market. Elutia aims to establish a presence in the $8 billion cardiac rhythm management market and adjacent $8 billion neurostimulation sectors.
The full commercial launch of EluPro is scheduled for January 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1612Followers
87Following
12KVisitors
Follow